Cargando…
MEK inhibitors for the treatment of non-small cell lung cancer
BRAF and KRAS are two key oncogenes in the RAS/RAF/MEK/MAPK signaling pathway. Concomitant mutations in both KRAS and BRAF genes have been identified in non-small cell lung cancer (NSCLC). They lead to the proliferation, differentiation, and apoptosis of tumor cells by activating the RAS/RAF/MEK/ERK...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7786519/ https://www.ncbi.nlm.nih.gov/pubmed/33402199 http://dx.doi.org/10.1186/s13045-020-01025-7 |
_version_ | 1783632642145517568 |
---|---|
author | Han, Jing Liu, Yang Yang, Sen Wu, Xuan Li, Hongle Wang, Qiming |
author_facet | Han, Jing Liu, Yang Yang, Sen Wu, Xuan Li, Hongle Wang, Qiming |
author_sort | Han, Jing |
collection | PubMed |
description | BRAF and KRAS are two key oncogenes in the RAS/RAF/MEK/MAPK signaling pathway. Concomitant mutations in both KRAS and BRAF genes have been identified in non-small cell lung cancer (NSCLC). They lead to the proliferation, differentiation, and apoptosis of tumor cells by activating the RAS/RAF/MEK/ERK signaling pathway. To date, agents that target RAS/RAF/MEK/ERK signaling pathway have been investigated in NSCLC patients harboring BRAF mutations. BRAF and MEK inhibitors have gained approval for the treatment of patients with NSCLC. According to the reported findings, the combination of MEK inhibitors with chemotherapy, immune checkpoint inhibitors, epidermal growth factor receptor-tyrosine kinase inhibitors or BRAF inhibitors is highly significant for improving clinical efficacy and causing delay in the occurrence of drug resistance. This review summarized the existing experimental results and presented ongoing clinical studies as well. However, further researches need to be conducted to indicate how we can combine other drugs with MEK inhibitors to significantly increase therapeutic effects on patients with lung cancer. |
format | Online Article Text |
id | pubmed-7786519 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-77865192021-01-07 MEK inhibitors for the treatment of non-small cell lung cancer Han, Jing Liu, Yang Yang, Sen Wu, Xuan Li, Hongle Wang, Qiming J Hematol Oncol Review BRAF and KRAS are two key oncogenes in the RAS/RAF/MEK/MAPK signaling pathway. Concomitant mutations in both KRAS and BRAF genes have been identified in non-small cell lung cancer (NSCLC). They lead to the proliferation, differentiation, and apoptosis of tumor cells by activating the RAS/RAF/MEK/ERK signaling pathway. To date, agents that target RAS/RAF/MEK/ERK signaling pathway have been investigated in NSCLC patients harboring BRAF mutations. BRAF and MEK inhibitors have gained approval for the treatment of patients with NSCLC. According to the reported findings, the combination of MEK inhibitors with chemotherapy, immune checkpoint inhibitors, epidermal growth factor receptor-tyrosine kinase inhibitors or BRAF inhibitors is highly significant for improving clinical efficacy and causing delay in the occurrence of drug resistance. This review summarized the existing experimental results and presented ongoing clinical studies as well. However, further researches need to be conducted to indicate how we can combine other drugs with MEK inhibitors to significantly increase therapeutic effects on patients with lung cancer. BioMed Central 2021-01-05 /pmc/articles/PMC7786519/ /pubmed/33402199 http://dx.doi.org/10.1186/s13045-020-01025-7 Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Review Han, Jing Liu, Yang Yang, Sen Wu, Xuan Li, Hongle Wang, Qiming MEK inhibitors for the treatment of non-small cell lung cancer |
title | MEK inhibitors for the treatment of non-small cell lung cancer |
title_full | MEK inhibitors for the treatment of non-small cell lung cancer |
title_fullStr | MEK inhibitors for the treatment of non-small cell lung cancer |
title_full_unstemmed | MEK inhibitors for the treatment of non-small cell lung cancer |
title_short | MEK inhibitors for the treatment of non-small cell lung cancer |
title_sort | mek inhibitors for the treatment of non-small cell lung cancer |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7786519/ https://www.ncbi.nlm.nih.gov/pubmed/33402199 http://dx.doi.org/10.1186/s13045-020-01025-7 |
work_keys_str_mv | AT hanjing mekinhibitorsforthetreatmentofnonsmallcelllungcancer AT liuyang mekinhibitorsforthetreatmentofnonsmallcelllungcancer AT yangsen mekinhibitorsforthetreatmentofnonsmallcelllungcancer AT wuxuan mekinhibitorsforthetreatmentofnonsmallcelllungcancer AT lihongle mekinhibitorsforthetreatmentofnonsmallcelllungcancer AT wangqiming mekinhibitorsforthetreatmentofnonsmallcelllungcancer |